ACLY

Across TCGA pan-cancer cohorts, ACLY mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACLY data layer compared with 29 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACLY mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACLY expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ACLY mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.965	0.866	.009	5	view →
PDAC	OS	Median	IV	0.395	0.937	.026	4	view →
LUAD	DFS	Tertile	III,IV	0.904	0.580	.040	3	view →
LSCC	OS	Median	II,III,IV	0.810	1.000	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACLY–CCRCC (DFS)

Open the CCRCC breakdown →